Cartesian Therapeutics said it has received rare pediatric disease designation from the U.S. Food and Drug Administration for its Descartes-08 treatment of juvenile dermatomyositis.
US FDA grants rare paediatric disease designation to Cartesian Therapeutics’ Descartes-08 to treat juvenile dermatomyositis: Gaithersburg, Maryland Tuesday, September 10, 2024, ...
Descartes-08, Cartesian’s lead mRNA cell therapy candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) product candidate targeting B-cell maturation antigen ...
Cartesian Therapeutics, Inc. (RNAC), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, ...
Juvenile dermatomyositis (JM for short ... your grand-daughter may have had weak muscles at the same time as her skin rash appeared, or she may have noticed muscle weakness weeks or months ...
I'm 87 and whenever I do some weeding in my garden, I get really dizzy. I take losartan for my blood pressure and have ...
[3] Dermatomyositis is a rare disease that affects the muscles and skin. The symptoms include rashes, muscle weakness, and ...